Juerg Lehmann

This inventor holds 19 USPTO granted patents and 15 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compositions. Top assignee: Arena Pharmaceuticals, Inc.. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juerg Lehmann. Retrieved from https://idiyas.com/inventor/juerg-lehmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 15)

% Patents Active = 73.7

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 5.9

ph-index = 9

Forward Citations = 207(Granted Patents)

Company Filing History:

19 out of 218

Arena Pharmaceuticals, Inc.

patents

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

5-HT Receptor Agonists

Pharmaceutical Compositions

GPR119 Modulators

Autoimmune Disorders

Inflammatory Disorders

Bone Mass Treatment

Metabolism Modulators

Tricyclic Acid Derivatives

Serotonin Receptor Modulators

Heteroaryl Derivatives

Indoline Derivatives

Pyrazole Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11395824 - 5-HTreceptor agonists and compositions and methods of use (2022-07-26),

2. 10894787 - Modulators of the GPR119 receptor and the treatment of disorders related thereto (2021-01-19),

3. 10781180 - 3-phenyl-pyrazole derivatives as modulators of the 5-HTserotonin receptor useful for the treatment of disorders related thereto (2020-09-22),

4. 10624900 - 5-HTreceptor agonists and compositions and methods of use (2020-04-21),

5. 10272094 - 5-HT2C receptor agonists and compositions and methods of use (2019-04-30),

6. 9676758 - 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto (2017-06-13),

7. 9522133 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2016-12-20),

8. 9126932 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2015-09-08),

9. 9108969 - Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders (2015-08-18),

10. 8785441 - 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto (2014-07-22),

11. 8580841 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders (2013-11-12),

12. 8546429 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2013-10-01),

13. 8415484 - Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders (2013-04-09),

14. 8362248 - Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto (2013-01-29),

15. 8101626 - GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto (2012-01-24),

Title: Juerg Lehmann: Innovator in Pharmaceutical Patents

Introduction

Juerg Lehmann is a prominent inventor based in San Diego, California, whose work has significantly contributed to the field of pharmaceuticals. With 19 patents under his name, Lehmann focuses on innovative solutions for various medical conditions, showcasing the power of innovation in healthcare.

Latest Patents

Lehmann's latest patents include groundbreaking work on 5-HT receptor agonists and compositions that modulate the activity of the 5-HT2C receptor. These compounds aim to assist in a variety of applications, such as weight management, treatment of obesity, and managing psychiatric disorders like schizophrenia and bulimia nervosa. Another noteworthy patent involves modulators of the GPR119 receptor, which are employed in the treatment of type 2 diabetes, obesity, and associated complications. The compounds described in these patents offer new avenues for addressing complex health issues through innovative pharmaceutical research.

Career Highlights

Lehmann has made a remarkable impact in the pharmaceutical industry through his position at Arena Pharmaceuticals, Inc. His research and inventions are essential in developing treatments that improve the quality of life for patients with various disorders. Each patent reflects a commitment to advancing medical understanding and finding effective remedies.

Collaborations

Throughout his career, Juerg Lehmann has collaborated with notable colleagues including Robert M. Jones and Yifeng Xiong. These partnerships highlight the importance of teamwork and shared expertise in driving innovation within pharmaceutical research.

Conclusion

Juerg Lehmann's contributions to the field of pharmaceuticals through his patents demonstrate the ongoing significance of innovation in addressing health challenges. His work at Arena Pharmaceuticals, Inc. not only paves the way for advancements in treatment methods but also exemplifies the collaborative spirit needed to tackle complex medical issues effectively.

Profile summary based on public USPTO records.